These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 17709460)

  • 101. Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia.
    Restrepo MI; Frei CR
    Am J Med; 2010 Apr; 123(4 Suppl):S39-46. PubMed ID: 20350634
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia.
    Belforti RK; Lagu T; Haessler S; Lindenauer PK; Pekow PS; Priya A; Zilberberg MD; Skiest D; Higgins TL; Stefan MS; Rothberg MB
    Clin Infect Dis; 2016 Jul; 63(1):1-9. PubMed ID: 27048748
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.
    Frei CR; Labreche MJ; Attridge RT
    Drugs; 2011 Apr; 71(6):757-70. PubMed ID: 21504252
    [TBL] [Abstract][Full Text] [Related]  

  • 104. β-lactam monotherapy is non-inferior to combination treatment for community-acquired pneumonia.
    Burki TK
    Lancet Respir Med; 2015 May; 3(5):347. PubMed ID: 25892353
    [No Abstract]   [Full Text] [Related]  

  • 105. Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.
    Pradelli J; Risso K; de Salvador FG; Cua E; Ruimy R; Roger PM
    Eur J Clin Microbiol Infect Dis; 2015 Mar; 34(3):511-8. PubMed ID: 25273975
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis.
    De la Calle C; Ternavasio-de la Vega HG; Morata L; Marco F; Cardozo C; García-Vidal C; Del Rio A; Cilloniz C; Torres A; Martínez JA; Mensa J; Soriano A
    J Infect; 2018 Apr; 76(4):342-347. PubMed ID: 29360520
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones.
    Metersky ML; Ma A; Houck PM; Bratzler DW
    Chest; 2007 Feb; 131(2):466-73. PubMed ID: 17296649
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Impact of infectious etiology on the outcome of Taiwanese patients hospitalized with community acquired pneumonia.
    Lee YT; Chen SC; Chan KC; Wu TC; Tsao SM; Chan CH
    J Infect Dev Ctries; 2013 Feb; 7(2):116-24. PubMed ID: 23416657
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
    Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.
    Laserna E; Sibila O; Fernandez JF; Maselli DJ; Mortensen EM; Anzueto A; Waterer G; Restrepo MI
    Chest; 2014 May; 145(5):1114-1120. PubMed ID: 24458223
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis.
    Ito A; Ishida T; Tachibana H; Tokumasu H; Yamazaki A; Washio Y
    Sci Rep; 2019 Dec; 9(1):18406. PubMed ID: 31804572
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
    Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
    Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Elderly patients with community-acquired pneumonia: optimal treatment strategies.
    Thiem U; Heppner HJ; Pientka L
    Drugs Aging; 2011 Jul; 28(7):519-37. PubMed ID: 21721597
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Does radiographic evidence of prior pulmonary tubercular infection influence the choice of empiric antibiotics for community-acquired pneumonia in a tuberculosis-endemic area?
    Jeng YY; Lin YT; Huang LJ; Chen TL; Wang FD; Fung CP; Liu CY
    J Microbiol Immunol Infect; 2010 Oct; 43(5):386-94. PubMed ID: 21075705
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Antimicrobial strategy for severe community-acquired legionnaires' disease: a multicentre retrospective observational study.
    Cecchini J; Tuffet S; Sonneville R; Fartoukh M; Mayaux J; Roux D; Kouatchet A; Boissier F; Tchir M; Thyrault M; Maury E; Jochmans S; Mekontso Dessap A; Brun-Buisson C; de Prost N
    J Antimicrob Chemother; 2017 May; 72(5):1502-1509. PubMed ID: 28204479
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning.
    König R; Cao X; Oswald M; Forstner C; Rohde G; Rupp J; Witzenrath M; Welte T; Kolditz M; Pletz M;
    Eur Respir J; 2019 Dec; 54(6):. PubMed ID: 31537702
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Community-acquired Haemophilus influenzae pneumonia--New insights from the CAPNETZ study.
    Forstner C; Rohde G; Rupp J; Schuette H; Ott SR; Hagel S; Harrison N; Thalhammer F; von Baum H; Suttorp N; Welte T; Pletz MW;
    J Infect; 2016 May; 72(5):554-63. PubMed ID: 26940505
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Update on the combination effect of macrolide antibiotics in community-acquired pneumonia.
    Emmet O'Brien M; Restrepo MI; Martin-Loeches I
    Respir Investig; 2015 Sep; 53(5):201-9. PubMed ID: 26344609
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Comparative Effectiveness of Beta-lactam Versus Macrolide Monotherapy in Children with Pneumonia Diagnosed in the Outpatient Setting.
    Ambroggio L; Test M; Metlay JP; Graf TR; Blosky MA; Macaluso M; Shah SS
    Pediatr Infect Dis J; 2015 Aug; 34(8):839-42. PubMed ID: 25955834
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.
    Epstein BJ; Gums JG
    Drugs; 2005; 65(14):1949-71. PubMed ID: 16162020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.